Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.

By S. Nissen, E. Tuzcu, Paul-Henry Schoenhagen, B. G. Brown, Peter Ganz, Robert A. Vogel, T. Crowe, G. Howard, Christopher J Cooper, Bruce R Brodie and 2 more. Journal of the American Medical Association (JAMA), 2004

2,444 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/1e47c81ad6cd6e3dc957d3e306e1090d89323965

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Peter Libby
2. J. Chapman
3. S. Grundy
4. A. Kontush
5. A. Lichtman
6. I. Tabas

In Endocrinology, Diabetes and Metabolism

1. S. Grundy
2. S. Nissen
3. Peter Libby
4. J. Chapman
5. A. Kontush
6. K. Wolski
7. Ralph DeFronzo

In Surgery

1. Peter Libby
2. E. Tuzcu
3. Paul-Henry Schoenhagen
4. S. Grundy
5. T. Crowe
6. J. Liao
7. J. Chapman
8. A. Kontush

Citations in the corpus

• Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. (2011, neutral): “Pedersen et al (IDEAL),16 2005d 27 (4) 62 (10) 47 (12) 125 (35) 16 4.”
• Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. (2006, methodology): “Prior publications have thoroughly described the methods for IVUS interrogation.(11,12,14,19) Following diagnostic angiography, the operator selected a target vessel for IVUS interrogation, defined as the longest and least-angulated vessel meeting inclusion criteria.”
• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. (2008, methodology): “PAV was selected as the primary efficacyparameterbecausethisendpointhas exhibitedthelowestvariabilityinmultiple previous IVUS trials for a diverse range of therapeutic interventions.(10-12,14-16)”
• Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. (2007, methodology): “Imaging studies have shown that statin-induced reductions in LDL-C slow atheroma disease progression and that achieving very low levels of LDL-C with high-intensity statin therapy may result in regression.(11) More recently, reductions in levels of the inflammatory biomarker CRP in patients treated ”
• Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis (2006, methodology): “9% reduction after 18 months of intensive therapy with 80 mg of atorvastatin in the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) study (Nissen et al., 2004; Birjmohun et al., 2005).”